logo
Anthros Chair V2 Review: Surprisingly Great

Anthros Chair V2 Review: Surprisingly Great

WIRED26-06-2025
It's rare for me to keep sitting on a chair I'm reviewing well after I've given it enough testing time. Usually, I want to hop back on my Herman Miller Embody, which feels just right for my body. But the Anthros V2 has been a pleasant surprise. It's been on my radar for several months, thanks to endless Instagram marketing reels, but honestly, those just made me even more skeptical.
Anthros is a newcomer to the scene, only launching the first version of the chair in 2023. It makes grand claims about improving your posture and offering better support than office stalwarts like Herman Miller. It doesn't help that the V2 chair is north of $2,000, though it seems to be on sale often enough for around $1,900.
But after nearly two months of sitting, the claims hold up—I find it more supportive than almost all the chairs I've tested, and my posture has been great. The Embody still holds a place in my heart, but the Anthros V2 might be the best chair for anyone looking to sharpen up their posture, especially if you've been dealing with back pain.
Pelvic Support
Photograph: Julian Chokkattu
The Anthros chair focuses on supporting the pelvis, not the lumbar, similar to Herman Miller's Aeron and Embody, except it gives you far more to work with when dialing in the backrest. After setting it up, I had a call with an Anthros ergonomics therapist, something that's included for every customer. The therapist looks at how you're sitting in the chair (via video call) and will make suggestions until you feel comfortable in the seat. I wish every luxe chair offered such a service.
The rear knobs on the left and right of the chair control the two-part backrest system. The right knob moves the lumbar backrest forward and back, and the left knob handles the top. I haven't sat on a chair that lets you adjust the backrest to this degree, and I find it helps tailor the chair precisely to your body shape. It's the top backrest that took me a little time to get used to.
On my first day in the chair, I felt a little sore because it almost felt like the chair was pushing in. In reality, there wasn't any pressure, and I started feeling my back gently resting on the backrest. It was my posture correcting itself; it felt straight as a whistle. I also appreciate the compact design, which proves that you don't need your whole back to be held up by a backrest to feel supported, much like how you don't need a headrest on an office chair if it's designed well.
I spent a lot of time reclining in this chair, and my posture didn't change. You can lock the recline with the front left knob, but I kept it unlocked on the tightest tension (via the front right knob), allowing me to gently slope back. I never felt uncomfortable. That might also be due to the plush Cloudfloat seat, which is thicker than what you'll find on most high-end office chairs.
My only gripe with this seat is that I found the depth lacking for my 6'4" frame. It leaves about six fingers' worth of a gap between the edge and the back of my knee, when it should ideally be two to three. It's not a deal-breaker, but I'd have liked to feel that coverage extend closer to my knee. The seat is the perfect width for me, though taller and bigger folks may find it constricting.
Got Your Back
Photograph: Julian Chokkattu
There's a good degree of customization when purchasing the chair. You can choose between a white or black frame, add fun back panels like wood or specific designs, and opt for fabric or leather upholstery. I've been sitting on the smooth Athlon Performance fabric, which hasn't shown any signs of pilling even after nearly two months of daily use.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Tim Scannell, Former Stryker President & COO, Named Chair of Longeviti Neuro Solutions Amid $10M Capital Infusion From Soleus Capital
Tim Scannell, Former Stryker President & COO, Named Chair of Longeviti Neuro Solutions Amid $10M Capital Infusion From Soleus Capital

Yahoo

time2 minutes ago

  • Yahoo

Tim Scannell, Former Stryker President & COO, Named Chair of Longeviti Neuro Solutions Amid $10M Capital Infusion From Soleus Capital

Appointment to Chair of the Board and Additional Growth Funding Accelerate Longeviti's Mission in Developing Platform Solutions for Complex Neurological Disorders BALTIMORE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Longeviti Neuro Solutions, a neurotechnology company with a focus on innovative platform solutions for complex brain disorders, today announces the appointment of Tim Scannell, former President & COO of Stryker Corporation, as Chair of its Board of Directors. The company also reveals a $10 million strategic capital partnership with Soleus Capital to accelerate hiring, product development, and medical education efforts in the United States and abroad. Scannell brings a wealth of experience in the medical device market having served in leadership positions with Stryker Corporation for over thirty years. He advanced from sales and marketing to executive leadership roles highlighted by ten years as Group President of MedSurg & Neurotechnology and three years as President and COO of Stryker. He was responsible for assisting in the selection and development of the strategies and talent that delivered over the last three decades and continues to deliver outstanding results today. Scannell is currently scaling MedTech businesses with his involvement as board representative and chair for multiple public and private companies, with the majority offering interaction with neurosciences and neurosurgeons. In his role as Chair, he will assist with formulating strategic plans and providing oversight while serving as a sounding board for management. Longeviti established a strategic capital partnership with Soleus Capital, a healthcare investment firm based in Greenwich, CT. The firm, which invests in the innovative areas of life sciences including medical technology, biotechnology, diagnostics, and life science tools, has committed $10 million in structured financing to fund key strategic priorities for Longeviti. With this capital, Longeviti is poised to accelerate talent acquisition needs, continued development of its groundbreaking neurotechnology platforms, expand its market presence, and continue delivering life-changing innovations that enhance patient care. 'Tim's appointment as Chair of the Board brings world-class leadership and unmatched insight from decades of success in building, and leading, high-performing MedTech companies. His experience will be instrumental as we sharpen our strategy and deepen our impact in neurotechnology. Coupled with the $10 million capital infusion from Soleus Capital, Longeviti now has the momentum to grow our team, advance critical research, and accelerate the development and delivery of life-changing solutions for patients with complex brain disorders,' shared Jesse Christopher, Co-Founder and CEO, Longeviti Neuro Solutions. 'I easily said 'yes' to joining the Board of Directors for Longeviti, mainly because of the talent. I've known several of Longeviti's leaders for years, and admire their tenacity, persistence, and goals to make an instrumental difference in the neuro industry. Longeviti's technology is revolutionary and will support the advancement of patient care in neurosciences, creating a value for the industry, our shareholders, and employees,' said Tim Scannell, Chair, Board of Directors, Longeviti Neuro Solutions and former President and COO, Stryker. 'I'm honored to share my experiences and opinions to support the success of Longeviti.' 'We were introduced to Longeviti by a respected key opinion leader who had firsthand experience using their innovative products in clinical practice. We were deeply impressed by the company's mission and strong operating results,' shared Ben Lund, Partner, Soleus Capital. 'It was clear to us that with the right capital support, Longeviti could scale its team, reach more clinicians and patients, and amplify its impact on those living with complex brain disorders. We are proud to be part of that growth.' About Longeviti Neuro Solutions ( Longeviti Neuro Solutions is a leading innovator in functional neurotechnology, dedicated to developing advanced solutions that improve the lives of patients with neurological conditions during and after surgery, while also returning them to anatomical normalcy. The Baltimore-based company has full manufacturing, packaging, designing, and sterilizing capabilities in-house with multiple FDA clearances, successful FDA audits, and ISO 13485 Certifications. Longeviti has 50 worldwide patents to date. Longeviti's mission is to develop innovative platform solutions for complex brain surgery. Its products are currently approved for use in over 120 hospitals across the globe. To date, Longeviti neurosurgical implants have helped over 4,000 patients. About Soleus Capital ( Soleus Capital is a healthcare investment firm based in Greenwich, CT. Founded in 2018, the company currently has ~$2B in assets under management. Soleus partners with companies across three strategies – public equity, private equity and structured credit – and across each of the life sciences subsectors – biotechnology, medical technology, life science tools and diagnostics. Contact: Nicole Halsey/Natalie Van Buskirk Polished Nichols PR & Marketing nicole@ natalie@ 410.952.2122/443.956.4765 A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

NYC officials to give update on Legionnaires' disease outbreak in Harlem
NYC officials to give update on Legionnaires' disease outbreak in Harlem

CBS News

time4 minutes ago

  • CBS News

NYC officials to give update on Legionnaires' disease outbreak in Harlem

A deadly Legionnaires' disease outbreak in New York City has set health and community leaders on a campaign to educate the public on ways to prevent the bacteria from growing and spreading. City Councilmember Yusef Salaam, New York Assemblyman Jordan Wright, and city Department of Health officials have scheduled a news conference Thursday at 3 p.m. to update the public on the outbreak in Harlem. You can watch the news conference live in the player above on CBS News New York. At least three people have died out of more than 70 cases since the Central Harlem Legionnaires' disease cluster was discovered on July 25, according to NYC Health. Officials believe they traced the outbreak to cooling towers on 11 buildings. Legionnaires' is a severe and potentially deadly form of pneumonia that grows in warm, stagnant water and spreads through mist in the air. Symptoms include cough, fever, chills, muscle aches and shortness of breath. So far, cases have been found in these zip codes: 10027, 10030, 10035, 10037 and 10039. It's feared the number of cases could rise as more people may have been exposed, but are not yet symptomatic. "It can take up to two weeks in certain people. Some people it can take a couple of days, but for the most part, it's between two days to 14 days," Tony Esselstyn, deputy chief medical officer at the NYC Department of Health and Hygiene, said. Most people are at a low risk, but the bacteria poses a greater threat to smokers and people over 50. Anyone with symptoms in the identified zip codes is urged to see a health care provider.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store